Omada’s 12-week GLP-1 study linked virtual support to greater weight loss. Read the body-composition findings and key study limitations.
On October 20, 2026, Omada Health reported results from a study of its GLP-1 Care Track, a virtual program supporting adults taking GLP-1 medication for weight loss.
The company announcement described a peer-reviewed evaluation published in Diabetes, Obesity and Metabolism. It compared the program with usual care over 12 weeks.
The study followed 245 adults with obesity who had started a GLP-1 medication within the previous eight weeks. Of those participants, 151 joined the program and 94 received usual care.
The headline finding was greater average weight loss in the program group. The more useful question is what that difference means for medication care, everyday support and body composition.
The biological question here concerns what changes during weight loss. Scale weight describes total body weight. Body composition asks how that weight is distributed, including the proportions attributed to fat and muscle.
Those are related questions, but they are not interchangeable. A lower number on the scale does not by itself describe the mix of tissues behind that change. This study paired weight outcomes with estimates of body-fat percentage and muscle-mass percentage.
The evaluation examined a broader model of care rather than a new drug mechanism. According to Omada’s announcement, its GLP-1 Care Track combined:
These components place nutrition and activity support around medication use. The proposed practical pathway is support for everyday behaviors rather than a separate biological action attributed to coaching. That makes the care environment part of the research question.
For readers, it helps to separate weight change from the support available during treatment. Our discussion of nutrition and strength alongside medication offers context for considering those goals together.
NewBeauty’s coverage puts coaching at the center of its headline. It also notes that the study was not randomized and was conducted by Omada, the company selling the program. The findings therefore describe an association between program participation and outcomes. They do not establish that the program caused the difference.
The available account does not explain how participants entered either group or report adjustment for baseline differences between them. It also does not provide medication types or doses. Details about adherence and attrition are absent, as are adverse-event results and a full accounting of funding and author disclosures.
The comparison group also needs careful description. Usual care could mean medication alone or participation in a non-Omada lifestyle program. In fact, 26% of that group reported using another lifestyle or wellness program during the study. Calling this a simple comparison of medication plus support versus medication without support would misrepresent the design.
Another issue is the bundled intervention. Coaching came alongside peer support and digital tools, as well as access to exercise expertise. The results do not identify which feature mattered or whether the combination was important.
Measurement deserves its own caution. Participants used at-home bioelectrical impedance scales for body-composition estimates. The available reporting gives neither the device model nor a validation protocol. Without those details, the measurement process is harder to assess.
The announcement provides no p-values or confidence intervals for the weight and body-composition comparisons. It does not specify statistical significance for those outcomes. The reported window is 12 weeks, with no longer-term maintenance or body-composition results described.
The practical response is to ask better questions about care rather than select a program based on a headline. Useful questions include:
These questions do not assume that everyone needs the same package of services. They help clarify what a program actually offers and whether those services address someone’s circumstances. A list of features is not the same thing as evidence that every feature improves outcomes.
At WeightRestart, our focus is clear and shame-free guidance about sustainable weight management. Here, that means looking at the support around treatment rather than interpreting a person’s progress as a measure of resolve. Medication choices and individual treatment decisions belong with a qualified clinician who can consider personal needs and safety.
According to Omada’s report, the program group showed larger average changes in the reported measures. The results were:
The last result needs particularly precise language. A muscle-mass percentage is a proportion of total weight, not an amount of muscle tissue. A larger proportion does not automatically mean someone gained muscle, because the denominator can change as total weight changes. The reported increase therefore should not become a claim that the program built muscle or proved muscle preservation.
The same care applies to the body-fat figures. Omada reported them as changes in body-fat percentage. Keeping that wording avoids turning the result into an unsupported claim about a specific amount of fat tissue lost.
Omada also reported greater improvements in well-being and physical functioning, along with confidence in the ability to lose weight. Its account did not provide numerical results for those outcomes. They add a potentially relevant daily-life dimension without allowing a precise estimate of the difference.
Our related coverage of interpreting body composition during obesity treatment provides another lens for reading these outcomes. The central habit is to ask what was actually measured before attaching a larger health claim to the result.
Taken together, the reported outcomes point toward a care question worth studying: how should support around medication be organized? They are more useful as evidence to refine that question than as a scorecard for judging an individual’s progress against a group average.
A useful next step would be an independently run randomized comparison that records medication exposure and safety alongside weight change. Researchers should also use clearly described body-composition methods and report absolute muscle mass where possible. Measures of physical function would help connect changes in body composition with outcomes that matter in daily life.
Future studies could test the program’s components separately. That would help clarify whether benefits are associated with activity planning or nutrition support, for example, rather than treating the entire package as a single explanation. Longer follow-up should also examine whether improvements persist and how support needs change over time.
What to watch next is whether stronger comparisons reproduce this pattern while showing meaningful improvements in health and functioning. For now, the study makes a reasonable case for asking about the support surrounding a prescription. It is a reason to examine care more carefully, not a basis for expecting the same result from any particular program.
WeightRestart shares research-led guidance on weight loss, metabolism, nutrition, strength, appetite, sleep and recovery. Our goal is to make complex health information clear, practical and useful for people building progress they can maintain.
Learn how to build a weight-management approach around better information, realistic expectations and habits you can keep using.
read the blog
